Literature DB >> 20228899

Semiparametric estimation of treatment effects given base-line covariates on an outcome measured after a post-randomization event occurs.

Yannis Jemiai1, Andrea Rotnitzky, Bryan E Shepherd, Peter B Gilbert.   

Abstract

We consider estimation, from a double-blind randomized trial, of treatment effect within levels of base-line covariates on an outcome that is measured after a post-treatment event E has occurred in the subpopulation 𝒫(E,E) that would experience event E regardless of treatment. Specifically, we consider estimation of the parameters γ indexing models for the outcome mean conditional on treatment and base-line covariates in the subpopulation 𝒫(E,E). Such parameters are not identified from randomized trial data but become identified if additionally it is assumed that the subpopulation 𝒫(Ē,E) of subjects that would experience event E under the second treatment but not under the first is empty and a parametric model for the conditional probability that a subject experiences event E if assigned to the first treatment given that the subject would experience the event if assigned to the second treatment, his or her outcome under the second treatment and his or her pretreatment covariates. We develop a class of estimating equations whose solutions comprise, up to asymptotic equivalence, all consistent and asymptotically normal estimators of γ under these two assumptions. In addition, we derive a locally semiparametric efficient estimator of γ. We apply our methods to estimate the effect on mean viral load of vaccine versus placebo after infection with human immunodeficiency virus (the event E) in a placebo-controlled randomized acquired immune deficiency syndrome vaccine tri.

Entities:  

Year:  2007        PMID: 20228899      PMCID: PMC2837843          DOI: 10.1111/j.1467-9868.2007.00615.x

Source DB:  PubMed          Journal:  J R Stat Soc Series B Stat Methodol        ISSN: 1369-7412            Impact factor:   4.488


  9 in total

1.  Principal stratification in causal inference.

Authors:  Constantine E Frangakis; Donald B Rubin
Journal:  Biometrics       Date:  2002-03       Impact factor: 2.571

2.  Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials.

Authors:  Peter B Gilbert; Ronald J Bosch; Michael G Hudgens
Journal:  Biometrics       Date:  2003-09       Impact factor: 2.571

3.  An estimator for treatment comparisons among survivors in randomized trials.

Authors:  Douglas Hayden; Donna K Pauler; David Schoenfeld
Journal:  Biometrics       Date:  2005-03       Impact factor: 2.571

4.  Estimating exposure effects by modelling the expectation of exposure conditional on confounders.

Authors:  J M Robins; S D Mark; W K Newey
Journal:  Biometrics       Date:  1992-06       Impact factor: 2.571

5.  Sensitivity analyses comparing outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials.

Authors:  Bryan E Shepherd; Peter B Gilbert; Yannis Jemiai; Andrea Rotnitzky
Journal:  Biometrics       Date:  2006-06       Impact factor: 2.571

6.  More powerful randomization-based p-values in double-blind trials with non-compliance.

Authors:  D B Rubin
Journal:  Stat Med       Date:  1998-02-15       Impact factor: 2.373

7.  An analytic method for randomized trials with informative censoring: Part 1.

Authors:  J M Robins
Journal:  Lifetime Data Anal       Date:  1995       Impact factor: 1.588

8.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

Authors:  Neil M Flynn; Donald N Forthal; Clayton D Harro; Franklyn N Judson; Kenneth H Mayer; Michael F Para
Journal:  J Infect Dis       Date:  2005-01-27       Impact factor: 5.226

9.  On the analysis of viral load endpoints in HIV vaccine trials.

Authors:  Michael G Hudgens; Antje Hoering; Steven G Self
Journal:  Stat Med       Date:  2003-07-30       Impact factor: 2.373

  9 in total
  15 in total

1.  Commentary on "Principal stratification - a goal or a tool?" by Judea Pearl.

Authors:  Peter B Gilbert; Michael G Hudgens; Julian Wolfson
Journal:  Int J Biostat       Date:  2011-09-20       Impact factor: 0.968

2.  Semiparametric estimation of the average causal effect of treatment on an outcome measured after a postrandomization event, with missing outcome data.

Authors:  Peter B Gilbert; Yuying Jin
Journal:  Biostatistics       Date:  2009-10-08       Impact factor: 5.899

3.  Principal stratification--uses and limitations.

Authors:  Tyler J Vanderweele
Journal:  Int J Biostat       Date:  2011-07-11       Impact factor: 0.968

4.  Randomization-Based Inference within Principal Strata.

Authors:  Tracy L Nolen; Michael G Hudgens
Journal:  J Am Stat Assoc       Date:  2011-06       Impact factor: 5.033

5.  Doubly robust estimation and causal inference in longitudinal studies with dropout and truncation by death.

Authors:  Michelle Shardell; Gregory E Hicks; Luigi Ferrucci
Journal:  Biostatistics       Date:  2014-07-04       Impact factor: 5.899

6.  Interference and Sensitivity Analysis.

Authors:  Tyler J VanderWeele; Eric J Tchetgen Tchetgen; M Elizabeth Halloran
Journal:  Stat Sci       Date:  2014-11       Impact factor: 2.901

7.  A simple method for principal strata effects when the outcome has been truncated due to death.

Authors:  Yasutaka Chiba; Tyler J VanderWeele
Journal:  Am J Epidemiol       Date:  2011-02-25       Impact factor: 4.897

8.  Post-randomization Biomarker Effect Modification Analysis in an HIV Vaccine Clinical Trial.

Authors:  Peter B Gilbert; Bryan S Blette; Bryan E Shepherd; Michael G Hudgens
Journal:  J Causal Inference       Date:  2020-07-25

9.  A Bayesian approach to estimating causal vaccine effects on binary post-infection outcomes.

Authors:  Jincheng Zhou; Haitao Chu; Michael G Hudgens; M Elizabeth Halloran
Journal:  Stat Med       Date:  2015-07-20       Impact factor: 2.373

10.  Rank-based principal stratum sensitivity analyses.

Authors:  X Lu; D V Mehrotra; B E Shepherd
Journal:  Stat Med       Date:  2013-05-19       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.